Anticoagulant drugs: VKA high dose vs vitamin K antagonist (VKA): Thromboembolic events
High‐dose VKA showed no clear difference in any thromboembolic event compared with standard‐dose VKA (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
High‐dose VKA vs standard‐dose VKA Any thromboembolic event · people with antiphospholipid syndrome and a history of stroke or thromboembolic events High‐dose VKA showed no clear difference in any thromboembolic event compared with standard‐dose VKA (low certainty). Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane Headline outcomes only | RR 2.22 [0.79, 6.23] | 2 studies · 223 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid… 2020 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.